Superior vena cava syndrome: an increasingly frequent complication of cardiac procedures

Chee, Cheng Ean; Bjarnason, Haraldur; Prasad, Abhiram

doi:10.1038/ncpcardio0850

Cited by 37 publications

(28 citation statements)

References 16 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-malignant conditions account for 15-40% of SVC obstructions in contemporary retrospective series. Among these cases, SVC thrombosis cases, which are associated with the presence of intravascular devices, including central venous catheters and cardiac pacemaker leads, have increased rapidly (29,30). The goal of management for SVC syndrome is to alleviate symptoms and treat the underlying disease.…”

Section: Ptcl-nos Ctclmentioning

confidence: 99%

Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: A case report and review of the literature

Yang

Zhang

2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. The peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive neoplasms that account for <15% of all non-Hodgkin's lymphoma cases in adults. Angioimmunoblastic T-cell lymphoma (AITL) is a specific subtype of PTCL. The tumor is frequently aggressive and there is currently no general consensus regarding an effective treatment strategy. The present study reports a case in which bortezomib combined with dexamethasone was used to treat refractory AITL. A 63-year-old woman was admitted to Sir Run Run Shaw Hospital, Zhejiang University School of Medicine (Zhejiang, China) on August 17, 2013. The patient had been diagnosed with AITL for 4 months and had experienced a relapse of symptoms for the 4 days prior to admission. The patient demonstrated fever and dyspnea, accompanied by severe edema in the face and lower limbs, which later spread to the right upper limb. The patient was treated with bortezomib plus dexamethasone, which rapidly relieved the symptoms. The patient was subsequently administered an additional 2 cycles of bortezomib-based chemotherapy and survived for an additional 4 months, prior to succumbing to the disease. Only a small number of studies have reported the use of bortezomib in the treatment of T-cell lymphoma. The present study suggested that bortezomib-based treatment may be a reliable, safe and effective alternative for the treatment of relapsed/refractory PTCL. The efficacy of bortezomib as a treatment for PTCL requires additional evaluation in future studies.

show abstract

Section: Ptcl-nos Ctclmentioning

confidence: 99%

Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: A case report and review of the literature

Yang

Zhang

2016

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Although SVC obstruction is mostly related to malignant process but many different causes have also been described. Among benign etiologies there are tuberculosis, fibrosing mediastinitis, thrombosis secondary to indwelling central venous devices or pacemaker leads, retrosternal thyroid, aortic aneurysm and thymoma [5].…”

Section: Discussionmentioning

confidence: 99%

“…Superior vena cava syndrome is characterized by superior vena cava obstruction with severe reduction in venous return. Compression of the vena cava may result from extra luminal compression by mass present in middle or anterior mediastinum including right paratracheal lymph nodes, lymphoma, thymoma, aortic aneurysm or any inflammatory process leading to fibrosing mediastinitis [1][2][3][4][5]. Intravascular thrombosis of SVC can also give rise to this entity but are mostly associated with malignancies.…”

Section: Introductionmentioning

confidence: 99%

Superior vena cava syndrome due to intravascular thrombosis in a patient with rheumatoid arthritis without antiphospholipid antibody syndrome: Is rheumatoid arthritis a separate hypercoagulable state

Dharmshaktu¹,

Bhowmick²,

Dhanwal³

2014

RusOMJ

View full text Add to dashboard Cite

show abstract

“…Several prothrombotic factors in patients with Fontan physiology (see later discussion) can increase the likelihood of SVC clot, as can smoking and the use of estrogencontaining medications, such as some oral contraceptives. 26 Superior vena cava syndrome can cause the head to be edematous and upper chest neck veins to be prominent. Elevation of the head of the bed to greater than 45 ° is used to decrease edema.…”

Section: Passive Venous Flow To the Lungsmentioning

confidence: 99%

Long-term Issues After the Fontan Procedure

McRae

2013

AACN Advanced Critical Care

View full text Add to dashboard Cite

The Fontan procedure is used to treat various serious congenital heart defects. Although many people who have had the procedure live productively into adulthood, as they age, they face several health issues due to the physiology of the Fontan circulation. This article reviews the 4 types of Fontan procedures and the changes caused by the surgery, including single-ventricle physiology, nonpulsatile pulmonary perfusion, systemic venous hypertension, and intracardiac scarring, as well as their sequelae. Key nursing assessment items and possible treatment strategies are reviewed. Additional topics, including pregnancy in patients who have undergone the procedure, infective endocarditis prophylaxis, and health-related quality of life, are briefly discussed. Options for Fontan failure, including Fontan conversion or transplantation, are presented. Potential future solutions are outlined.

show abstract

Superior vena cava syndrome: an increasingly frequent complication of cardiac procedures

Abstract: Anticoagulation, catheter-directed thrombolytic therapy, mechanical thrombectomy, pericardiocentesis.

Cited by 37 publications

References 16 publications

Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: A case report and review of the literature

Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: A case report and review of the literature

Superior vena cava syndrome due to intravascular thrombosis in a patient with rheumatoid arthritis without antiphospholipid antibody syndrome: Is rheumatoid arthritis a separate hypercoagulable state

Long-term Issues After the Fontan Procedure

Contact Info

Product

Resources

About